FIELD: chemistry.
SUBSTANCE: described is a composition for treating cancer, containing the main type of HER2 antibody, which is linked with the II domain in HER2, and its versions on amino acid sequence, with a leader elongation at the amino-end.
EFFECT: invention increases assortment of drugs, used for treating cancer.
6 cl, 31 dwg, 7 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION CONTAINING ANTIBODY BINDING TO DOMAIN II OF HER2, AND ITS ACIDIC VERSIONS | 2009 |
|
RU2543664C2 |
| INTRODUCTION OF FIXED DOSES OF HER-ANTIBODIES | 2005 |
|
RU2438705C2 |
| THERAPY OF MALIGNANT TUMOR, RESISTANT TO PLATINUM-BASED MEDICATIONS | 2005 |
|
RU2403065C2 |
| COMPOSITIONS OF ANTIBODIES | 2005 |
|
RU2426554C2 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
| VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS | 2014 |
|
RU2737727C2 |
| MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2 | 2003 |
|
RU2338751C2 |
| BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES | 2016 |
|
RU2653443C2 |
| NEUREGULIN ANTAGONISTS AND USE THEREOF IN TREATING MALIGNANT GROWTH | 2011 |
|
RU2587619C2 |
| ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
